U.S. Cardiac Resynchronization Therapy Market Size & Outlook
U.S. cardiac resynchronization therapy market, 2018-2030 (US$M)
Related Markets
U.S. cardiac resynchronization therapy market highlights
- The U.S. cardiac resynchronization therapy market generated a revenue of USD 1,955.5 million in 2023 and is expected to reach USD 2,840.3 million by 2030.
- The U.S. market is expected to grow at a CAGR of 5.5% from 2024 to 2030.
- In terms of segment, crt-defibrillator was the largest revenue generating product in 2023.
- CRT-Pacemaker is the most lucrative product segment registering the fastest growth during the forecast period.
Cardiac resynchronization therapy market data book summary
| Market revenue in 2023 | USD 1,955.5 million |
| Market revenue in 2030 | USD 2,840.3 million |
| Growth rate | 5.5% (CAGR from 2023 to 2030) |
| Largest segment | Crt-defibrillator |
| Fastest growing segment | CRT-Pacemaker |
| Historical data | 2018 - 2022 |
| Base year | 2023 |
| Forecast period | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | CRT-Defibrillator, CRT-Pacemaker |
| Key market players worldwide | Medtronic PLC, Abbott Laboratories, Boston Scientific Corp, BIOTRONIK, MicroPort Scientific Corp, LivaNova PLC |
Other key industry trends
- In terms of revenue, U.S. accounted for 43.9% of the global cardiac resynchronization therapy market in 2023.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In North America, U.S. cardiac resynchronization therapy market is projected to lead the regional market in terms of revenue in 2030.
- Canada is the fastest growing regional market in North America and is projected to reach USD 528.6 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Cardiac Resynchronization Therapy Market Scope
Cardiac Resynchronization Therapy Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
U.S. cardiac resynchronization therapy market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cardiac resynchronization therapy market will help companies and investors design strategic landscapes.
Crt-defibrillator was the largest segment with a revenue share of 50.37% in 2023. Horizon Databook has segmented the U.S. cardiac resynchronization therapy market based on crt-defibrillator, crt-pacemaker covering the revenue growth of each sub-segment from 2018 to 2030.
Increasing mortality rate due to cardiac disorders is expected to boost growth of the U.S. market. For instance, according to the CDC, in the U.S., 1 in every 4 deaths occurs due to cardiac disorders, as of September 2021. Moreover, heart disease is among the leading causes of deaths in the country.
The U.S. CRT market is anticipated to witness significant growth due to the presence of favorable government policies to improve cardiovascular health. For instance, the National Health and Nutrition Examination Survey collects data from the U.S. population to assess the prevalence of CVDs and its risk factors (such as tobacco use, negative dietary habits, or physical inactivity) as well as biometric measures (DNA repositories & biospecimen).
Reasons to subscribe to U.S. cardiac resynchronization therapy market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of U.S. cardiac resynchronization therapy market databook
-
Our clientele includes a mix of cardiac resynchronization therapy market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. cardiac resynchronization therapy market , including forecasts for subscribers. This country databook contains high-level insights into U.S. cardiac resynchronization therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
U.S. cardiac resynchronization therapy market size, by product, 2018-2030 (US$M)
U.S. Cardiac Resynchronization Therapy Market Outlook Share, 2023 & 2030 (US$M)
Related industry reports
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
